New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 1, 2010, Pages 5-18

  Tan, Thean Hsiang ^a   Pranavan, Ganesalingam ^b   Haxhimolla, Hodo Z ^b   Yip, Desmond ^b,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b CANBERRA HOSPITAL   (Australia)

^c The Australian National University   (Australia)

Author keywords

Anti angiogenesis; Metastatic renal cell carcinoma; MTOR inhibitor; Oral multi kinase inhibitor; Targeted therapy

Indexed keywords

AFINITOR; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CYTOKINE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IRINOTECAN; IXABEPILONE; LAPATINIB; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PAZOPANIB; PLACEBO; RAPAMYCIN; RETINOIC ACID; RIBAVIRIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VITESPEN;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ALOPECIA; ANOREXIA; ARTERY THROMBOSIS; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HAIR DISCOLORATION; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; IMMUNOMODULATION; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LOW DRUG DOSE; MALAISE; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PALLIATIVE THERAPY; PANCYTOPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RASH; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; SOMNOLENCE; STOMATITIS; SUICIDE ATTEMPT; SYSTEMIC THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VEIN THROMBOSIS; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 77951211610     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01277.x     Document Type: Review

References (120)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-92.
4. Cancer in Australia: An Overview, 2006 2007, http://www.aihw.gov.au, Australian Institute of Health and Welfare and Australasian Association of Cancer Registries, Cancer series no 37 Cat No CAN 32, AIHW, Canberra, cited 4 July 2009]. Available from:
5. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996, 335:865-75.
6. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601-8.
7. Lam JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 2006, 24:5565-75.
8. Leibovich BC, Blute ML, Cheville JC. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-71.
9. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-40.
10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-96.
11. Mekhail TM, Abou-Jawde RM, Boumerhi G. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-41.
12. Gommersall L, Hayne D, Lynch C, Joseph JV, Arya M, Patel HR. Allogeneic stem-cell transplantation for renal-cell cancer. Lancet Oncol 2004, 5:561-7.
13. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007, 12:1404-15.
14. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999, 353:14-17. Medical Research Council Renal Cancer Collaborators
15. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, (3):CD001425.
16. Musselman DL, Lawson DH, Gumnick JF. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-6.
17. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007, 103:83-90.
18. Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12:96-100.
19. Schaefer M, Schwaiger M, Garkisch AS. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005, 42:793-8.
20. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-96.
21. McDermott DF, Regan MM, Clark JI. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-41.
22. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 2006, 24:5584-92.
23. Dutcher J, Atkins MB, Margolin K. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001, 18:209-19.
24. Childs R, Chernoff A, Contentin N. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343:750-8.
25. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998, 29:301-13.
26. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002, 20:2017-24.
27. Ueno NT, Cheng YC, Rondon G. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003, 102:3829-36.
28. Pedrazzoli P, Da Prada GA, Giorgiani G. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002, 94:2409-15.
29. Hentschke P, Barkholt L, Uzunel M. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003, 31:253-61.
30. Baron F, Frere P, Baudoux E, Sautois B, Fillet G, Beguin Y. Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica 2003, 88:478-80.
31. Blaise D, Bay JO, Faucher C. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004, 103:435-41.
32. Barkholt L, Bregni M, Remberger M. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006, 17:1134-40.
33. Artz AS, Van Besien K, Zimmerman T. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: the University of Chicago experience. Bone Marrow Transplant 2005, 35:253-60.
34. Peccatori J, Barkholt L, Demirer T. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005, 104:2099-103.
35. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-5S.
36. Desai J, Gurney H, Pavlakis N, McArthur GA, ID D. Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: recommendations for patient management. Asia-Pac J Clin Oncol 2007, 3:167-76.
37. Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-56.
38. Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-24.
39. Motzer RJ, Hutson TE, Tomczak P. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-90.
40. Negrier S, Figlin R, Hutson T. Overall survival with sunitinib versus interferon (IFN-a) as first-line treatment of metastatic renal cell carcinoma (MRCC). Ann Oncol 2008, 19(8). Suppl.): Abstract 588PD
41. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007, 1(2):S41-S54. Suppl
42. Ratain MJ, Eisen T, Stadler WM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-12.
43. Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-34.
44. Bokermeyer C, Porta C, Beck J. Efficacy and safety of sorafenib in patients with brain and bone metastases: result from a large open-label, non-comparative phase III study of sorafenib in European patients with advanced RCC (EU-ARCCS). Ann Oncol 2008, 19(8). Suppl.): Abstract 595P
45. Porta C, Bracada S, Beck J. Efficacy and safety of sorafenib in elderly patients: results from a large open-label, non-comparative phase III study in European patients with advanced RCC (EU ARCCS). Ann Oncol 2008, 19(8). Suppl.): Abstract 596P
46. Elsen T, Beck J, Procopio G. Large open-label, non-comparative phase III study of sorafenib in European patients with advanced RCC (EU-ARCSS) - subgroup analysis of patients with and without baseline clinical cardiovascular disease (CCD). Ann Oncol 2008, 19(8). Suppl.): Abstract 602P
47. Escudier B, Eisen T, Stadler WM. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-18.
48. Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-81.
49. Raymond E, Alexandre J, Faivre S. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-47.
50. Hidalgo M, Buckner JC, Erlichman C. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006, 12:5755-63.
51. Atkins MB, Hidalgo M, Stadler WM. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-18.
52. Escudier B, Ravaud A, Oudard S, Eisen T. Phase-3 randomized trial of everolimus vs. placebo in metastatic renal cell carcinoma. Ann Oncol 2008, 19(8). Suppl.): Abstract 720
53. Yang JC, Haworth L, Sherry RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-34.
54. Bukowski RM, Kabbinavar FF, Figlin RA. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007, 25:4536-41.
55. Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-11.
56. Rini BI, Halabi S, Rosenberg JE. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-8.
57. Escudier B, Bellmunt J, Negrier S. Randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (RCC). J Clin Oncol 2009, 15s. Suppl): Abstract 5020
58. Rini BI, Halabi S, Rosenberg JE. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastasis renal cell carcinoma (RCC). Results of overall survival for CALBG 90206. J Clin Oncol 2009, 18s. Suppl): Abstract LBA5019
59. Geyer CE, Forster J, Lindquist D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-43.
60. Merseburger AS, Hennenlotter J, Simon P. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 2005, 25:1901-7.
61. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 2005, 65:5221-30.
62. Ravaud A, Hawkins R, Gardner JP. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008, 26:2285-91.
63. Hutson TE, Davis ID, Machiels JP. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Ann Oncol 2008, 19(8). Suppl.): Abstract 5780
64. Rixie O, Bukowski RM, Michaelson MD. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975-84.
65. McDonald MW, Diokno AC, Seski JC, Menon KM. Measurement of progesterone receptor in human renal cell carcinoma and normal renal tissue. J Surg Oncol 1983, 22:164-6.
66. Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977, 9:277-88.
67. Linehan WM, Bates SE, Yang JC. Cancer of the kidney. Cancer Principles & Practice of Oncology 2005, 1139-68. DeVita VT, Hellman S, Rosenberg SA. In, eds, 7th, edn., Lippincott Williams & Wilkins, Philadelphia PA
68. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995, 22:42-60.
69. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-5.
70. Elsen T, Boshoff C, Mak I. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82:812-17.
71. Amato R. Thalidomide for recurrent renal-cell cancer in a 40-year-old man. Oncology (Williston Park) 2000, 14:33-6.
72. Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-71.
73. Motzer RJ, Berg W, Ginsberg M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002, 20:302-6.
74. Li Z, Amato R, Papandreou C, Escudier B. Phase II study of thalidomide for patients with metastatic renal cell carcinoma progressing after interleukin-2 based therapy. Proc Am Soc Clin Oncol 2001, 20(180). Suppl.): Abstract 717
75. Escudier B, Lassau N, Couanet D. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002, 13:1029-35.
76. Novik Y, Dutcher JP, Larkin M, Escudier B. Phase II study of thalidomide in advanced refractory metastatic renal cell carcinoma: a single institution experience. Proc Am Soc Clin Oncol 2001, 20(265). Suppl.): Abstract 1057
77. Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 2002, 20:389-93.
78. Interferon alfa-2b with or without thalidomide in treating patients with metastatic or unresectable kidney cancer. http://clinicaltrials.gov/ct2/show/NCT00005966, ClinicalTrials.gov identifier: NCT00005966 [homepage on the Internet], cited 4 February 2009]. Available from:
79. Combination therapy with 5-fluorouracil, interferon-a, interleukin-2 & thalidomide for metastatic, advanced or recurrent renal cell carcinoma. http://clinicaltrials.gov/ct2/show/NCT00277017?term=combination+therapy+5FU%2C+interferon%2C+interleukin+thalidomide+for+metastatic+renal+cell+carcinoma&rank=1, ClinicalTrials.gov identifier: NCT00277017 [homepage on the Internet], cited 4 August 2009]. Available from:
80. Thalidomide and docetaxel in treating patients with advanced cancer. http://clinicaltrials.gov/ct2/show/NCT00049296?term=thalidomide+and+docetaxel+in+treating+patients+advanced+cancer&rank=1, ClinicalTrials.gov identifier: NCT00049296 [homepage on the Internet], cited 4 August 2009]. Available from:
81. A trial of thalidomide and capecitabine in metastatic renal cell carcinoma. http://clinicaltrials.gov/ct2/show/NCT00226980?term=trial+of+thalidomide+and+capecitabine+in+metastatic+renal+cell+carcinoma&rank=1, ClinicalTrials.gov identifier: NCT00226980 [homepage on the Internet], cited 4 August 2009]. Available from:
82. PEG-interferon alfa-2b, sargramostim, and thalidomide in treating patients with metastatic kidney cacner. http://clinicaltrials.gov/ct2/show/NCT00090870, ClinicalTrials.gov identifier: NCT00090870 [homepage on the Internet], cited 4 August 2009]. Available from:
83. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977, 117:272-5.
84. Marcus SG, Choyke PL, Reiter R. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993, 150:463-6.
85. Flanigan RC, Salmon SE, Blumenstein BA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-9.
86. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-70.
87. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-6.
88. Barbastefano J, Garcia JA, Elson P. Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival (PFS) in metastatic renal cell carcinoma (mRCC) in patients (Pts) treated with VGEF-targeted therapy. J Clin Oncol 2009, 15s. Suppl): Abstract 5095
89. Margulis V, Matin SF, Tannir N. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009, 73:337-41.
90. Gill IS, Kavoussi LR, Lane BR. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007, 178:41-6.
91. Eisenberg MS, Meng MV, Master VA. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol 2006, 20:504-8.
92. Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS, Novick AC. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2004, 64:930-4.
93. Steinberg AP, Finelli A, Desai MM. Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors. J Urol 2004, 172:2172-6.
94. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology 2006, 68:528-32.
95. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998, 16:2261-6.
96. Tolia BM, Whitmore WF. Solitary metastasis from renal cell carcinoma. J Urol 1975, 114:836-8.
97. Kierney PC, van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994, 1:345-52.
98. Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 1992, 54:33-8.
99. Golimbu M, Al-Askari S, Tessler A, Morales P. Aggressive treatment of metastatic renal cancer. J Urol 1986, 136:805-7.
100. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. 1969. J Urol 2002, 167:873-5.
101. Wood C, Srivastava P, Bukowski R. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-54.
102. Fleischmann J, Alyskewycz M, Flanigan RC. Stage III renal cell carcinoma: staging subcategories and prognosis. 1997, Presented at Am Urol Assoc Annual Meeting 1997: April 10-2
103. Messing EM, Manola J, Wilding G. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-22.
104. Pizzocaro G, Piva L, Colavita M. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425-31.
105. Clark JI, Atkins MB, Urba WJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-40.
106. Poster DS, Bruno S, Penta JS, Pinna K, Vilk P, Macdonald JS. Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma. Am J Clin Oncol 1982, 5:53-60.
107. Naito S, Kumazawa J, Omoto T. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol 1997, 4:8-12.
108. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987, 13:665-72.
109. Kjaer M, Iversen P, Hvidt V. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987, 21:285-9.
110. Finney R. The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br J Urol 1973, 45:258-69.
111. Pizzocaro G, Piva L, Di Fronzo G. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987, 138:1379-81.
112. Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 2008, 18:474-80.
113. Jocham D, Richter A, Hoffmann L. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363:594-9.
114. Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. http://clinicaltrials.gov/ct2/show/NCT00492258, ClinicalTrials.gov identifier: NCT00492258 [homepage on the Internet], cited 4 August 2009]. Available from:
115. A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). http://clinicaltrials.gov/ct2/show/NCT00375674, ClinicalTrials.gov identifier: NCT00375674 [homepage on the Internet], cited cited 4 August 2009]. Available from:
116. Sunitinib or sorefenib in treating patients with kidney cancer that was removed by surgery. http://clinicaltrials.gov/ct2/show/NCT00326898, ClinicalTrials.gov identifier: NCT00326898 [homepage on the Internet], cited 4 August 2009]. Available from:
117. Porzsolt F. Adjuvant therapy of renal cell cancer with interferon alpha-2a. Proc Am Soc Clin Oncol 1992, 11(202). Suppl.): Abstract 622
118. Atzpodien J, Kirchner H, Rebmann U. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2006, 95:463-9.
119. Repmann R, Wagner S, Richter A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res 1997, 17:2879-82.
120. Repmann R, Goldschmidt AJ, Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 2003, 23:969-74.